Arcus Biosciences annual cash and equivalents
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Arcus Biosciences Cash & Equivalents Growth & History (RCUS)
Arcus Biosciences's cash and equivalents was $222.0M for fiscal 2025.
View full Arcus Biosciences company overviewArcus Biosciences annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $222.0M | $72.0M | +48.00% |
| 2024 | 2024-12-31 | $150.0M | $23.0M | +18.11% |
| 2023 | 2023-12-31 | $127.0M | −$79.0M | −38.35% |
| 2022 | 2022-12-31 | $206.0M | $58.0M | +39.19% |
| 2021 | 2021-12-31 | $148.0M | −$25.4M | −14.66% |
| 2020 | 2020-12-31 | $173.4M | $115.5M | +199.32% |
| 2019 | 2019-12-31 | $57.9M | −$13.1M | −18.47% |
| 2018 | 2018-12-31 | $71.1M | −$27.4M | −27.80% |
| 2017 | 2017-12-31 | $98.4M | $33.3M | +51.05% |
| 2016 | 2016-12-31 | $65.2M | — | — |
Arcus Biosciences quarterly cash and equivalents
Q4.16
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $150.0M | −$98.0M | −39.52% |
| Q1 2026 | 2026-03-31 | $201.0M | $9.0M | +4.69% |
| Q4 2025 | 2025-12-31 | $222.0M | $72.0M | +48.00% |
| Q3 2025 | 2025-09-30 | $238.0M | $37.0M | +18.41% |
| Q2 2025 | 2025-06-30 | $248.0M | $92.0M | +58.97% |
| Q1 2025 | 2025-03-31 | $192.0M | $7.0M | +3.78% |
| Q4 2024 | 2024-12-31 | $150.0M | $23.0M | +18.11% |
| Q3 2024 | 2024-09-30 | $201.0M | $17.0M | +9.24% |
| Q2 2024 | 2024-06-30 | $156.0M | −$74.0M | −32.17% |
| Q1 2024 | 2024-03-31 | $185.0M | −$53.0M | −22.27% |
| Q4 2023 | 2023-12-31 | $127.0M | −$79.0M | −38.35% |
| Q3 2023 | 2023-09-30 | $184.0M | −$34.0M | −15.60% |
| Q2 2023 | 2023-06-30 | $230.0M | −$43.0M | −15.75% |
| Q1 2023 | 2023-03-31 | $238.0M | −$311.0M | −56.65% |
| Q4 2022 | 2022-12-31 | $206.0M | $58.0M | +39.19% |
| Q3 2022 | 2022-09-30 | $218.0M | $38.6M | +21.49% |
| Q2 2022 | 2022-06-30 | $273.0M | −$47.5M | −14.82% |
| Q1 2022 | 2022-03-31 | $549.0M | $158.7M | +40.68% |
| Q4 2021 | 2021-12-31 | $148.0M | −$25.4M | −14.66% |
| Q3 2021 | 2021-09-30 | $179.4M | −$42.4M | −19.12% |
| Q2 2021 | 2021-06-30 | $320.5M | $35.3M | +12.38% |
| Q1 2021 | 2021-03-31 | $390.3M | $322.9M | +479.66% |
| Q4 2020 | 2020-12-31 | $173.4M | $115.5M | +199.32% |
| Q3 2020 | 2020-09-30 | $221.8M | $142.9M | +180.85% |
| Q2 2020 | 2020-06-30 | $285.2M | $209.1M | +274.91% |
| Q1 2020 | 2020-03-31 | $67.3M | −$1.2M | −1.71% |
| Q4 2019 | 2019-12-31 | $57.9M | −$13.1M | −18.47% |
| Q3 2019 | 2019-09-30 | $79.0M | $4.1M | +5.48% |
| Q2 2019 | 2019-06-30 | $76.1M | −$93.9M | −55.25% |
| Q1 2019 | 2019-03-31 | $68.5M | −$129.6M | −65.42% |
| Q4 2018 | 2018-12-31 | $71.1M | −$27.4M | −27.80% |
| Q3 2018 | 2018-09-30 | $74.9M | — | — |
| Q2 2018 | 2018-06-30 | $170.0M | — | — |
| Q1 2018 | 2018-03-31 | $198.1M | — | — |
| Q4 2017 | 2017-12-31 | $98.4M | $33.3M | +51.05% |
| Q4 2016 | 2016-12-31 | $65.2M | — | — |
Arcus Biosciences cash and equivalents trends
Over the last five fiscal years, Arcus Biosciences's cash and equivalents increased from $173.4M to $222.0M, a change of $48.6M. The latest reported quarter, Q2 2026, shows $150.0M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcus Biosciences source filings ↗Community posts
Arcus sets $17.50 share price for $250 million equity financing
Arcus Biosciences ($RCUS) priced an underwritten public offering of 14,285,715 new common shares at $17.50 apiece, targeting approximately $250 million in gross proceeds. The company is selling all of the shares, so the financing would add ...
Arcus reports additional kidney-cancer data supporting casdatifan development
Arcus Biosciences ($RCUS) released additional results from the ARC-20 program evaluating casdatifan in kidney cancer. Across pooled monotherapy cohorts involving 121 heavily pretreated patients, median overall survival was 35 months, median ...
